✦ LIBER ✦

Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register

✍ Scribed by Askling, J. (author);Baecklund, E. (author);Granath, F. (author);Geborek, P. (author);Fored, M. (author);Backlin, C. (author);Bertilsson, L. (author);Cöster, L. (author);Jacobsson, L. T. (author);Lindblad, S. (author);Lysholm, J. (author);Rantapää-Dahlqvist, S. (author);Saxne, T. (author);Van Vollenhoven, R. (author);Klareskog, L. (author);Feltelius, N. (author)

Book ID: 118006873
Publisher: BMJ Publishing Group
Year: 2008
Tongue: English
Weight: 147 KB
Volume: 68
Category: Article
ISSN: 0003-4967
DOI: 10.1136/ard.2007.085852

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Anti-tumour necrosis factor therapy in r

Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register

✍ Askling, J. (author);Baecklund, E. (author);Granath, F. (author);Geborek, P. (au 📂 Article 📅 2008 🏛 BMJ Publishing Group 🌐 English ⚖ 147 KB

Haematopoietic malignancies in rheumatoi

Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists

✍ Askling, J 📂 Article 📅 2005 🏛 BMJ Publishing Group 🌐 English ⚖ 110 KB

Anti–tumor necrosis factor α therapy and

Anti–tumor necrosis factor α therapy and the risk of lymphoma in rheumatoid arthritis: No clear answer

✍ Deborah P. M. Symmons; Alan J. Silman 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 50 KB 👁 1 views

The authors are the principal investigators of the British Society of Rheumatology (BSR) Biologics Register. The BSR receives financial support for the Register from the manufacturers of biologic agents currently licensed for use in the treatment of patients with inflammatory rheumatic diseases. The

Association between anti-tumour necrosis

Association between anti-tumour necrosis factor therapy and risk of ischaemic stroke in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registers-Rheumatoid Arthritis (BSRBR-RA)

✍ Low, Audrey SL; Lunt, Mark; Mercer, Louise K; Galloway, James B; Davies, Rebecca 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 47 KB

Anti–tumor necrosis factor α therapy and

Anti–tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis

✍ Sebastian Schneeweiss; Soko Setoguchi; Michael E. Weinblatt; Jeffrey N. Katz; Je 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB 👁 1 views

## Abstract ## Objective To assess the association between the initiation of anti–tumor necrosis factor α (anti‐TNFα) therapy and the risk of serious bacterial infections in routine care. ## Methods This was a cohort study of patients with rheumatoid arthritis (RA) in whom specific disease‐modif

Lymphoma in rheumatoid arthritis: The ef

Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti–tumor necrosis factor therapy in 18,572 patients

✍ Frederick Wolfe; Kaleb Michaud 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 2 views

## Abstract ## Objective The risk of lymphoma is increased in patients with rheumatoid arthritis (RA), and spontaneous reporting suggests that methotrexate (MTX) and anti–tumor necrosis factor (anti‐TNF) therapy might be associated independently with an increased risk of lymphoma. However, data fr